Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Thermo Fisher Scientific launches Acclaim Surfactant Plus and MAbPac SCX-10 chromatography columns

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced new chromatography columns, the Thermo Scientific Acclaim Surfactant Plus and smaller-particle sized Thermo Scientific MAbPac SCX-10.

From Thermo Fisher Scientific Inc. 12 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Emergent BioSolutions fourth quarter total revenues increase to $107.9M

Emergent BioSolutions Inc. announced today its financial results for the fourth quarter and full year ended December 31, 2011.

9 Mar 2012

PharmAthene revenue increases to $24.3M for year ended December 31, 2011

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2011.

9 Mar 2012

XMetA can control blood glucose levels in patients with diabetes

XOMA Corporation announced that its study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association's journal Diabetes.

8 Mar 2012

New inexpensive medical sensor may simplify diagnosis of diseases

An inexpensive new medical sensor has the potential to simplify the diagnosis of diseases ranging from life-threatening immune deficiencies to the common cold, according to its inventors at the Stanford University School of Medicine.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

A&G, Mayo Medical sign license agreement for new progranulin blood test for FTD

Mayo Clinic today announced that Mayo Medical Laboratories has signed an agreement with A&G Pharmaceutical, Inc. and will receive a non-exclusive license to certain patent rights and proprietary antibody reagents for the detection and measurement of progranulin in blood.

7 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Blocking Plexin B1 protein can prevent formation of breast cancer metastases

In particularly aggressive forms of breast cancer, cancer cells can settle in other organs and form metastases there. Once such metastases form, complete recovery is rare. Consequently, it is enormously important to prevent the metastasisation of the breast cancer cells. The success, however, achieved by using existing forms of therapy is limited.

6 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

Microneedle vaccine patches may effectively protect against flu

Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses by the Emory and Georgia Tech research team helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

6 Mar 2012

Santarus fourth quarter total revenues increase 65% to $42.6M

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

5 Mar 2012

FDA accepts Eisai's resubmission of perampanel NDA for review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.

5 Mar 2012

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

Study: Bioavailability similar among four subcutaneous IgG preparations

Data presented by CSL Behring today suggest that the bioavailability of immunoglobulin G (IgG) therapies is consistent when patients with primary immunodeficiencies switch from one IgG product to another by the subcutaneous route.

5 Mar 2012

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

Genentech, a member of the Roche Group, today announced that preliminary results from the ADACTA (ADalimumab ACTemrA) study showed that patients who received ACTEMRA (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity after 24 weeks than those given adalimumab monotherapy.

2 Mar 2012

BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB and its collaborator Genentech, a member of the Roche Group, announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease.

2 Mar 2012

NKT cells may reduce monocytes accumulation, prevent lung injury in severe flu

While some scientists report engineering a super virulent strain of the H5N1 influenza virus, which could potentially wipe out a significant percentage of the human population, another group of researchers from the United Kingdom now reports a discovery that may one day help mitigate the deadly effects of all flu strains.

1 Mar 2012